Infection is common in babies in neonatal intensive care units. It may be overwhelming but early signs are largely non-specific and babies from such a population often receive broad range antibiotics before the results of cultures are available. The combination of an aminoglycoside and a penicillin is widely used.' Recently, the emergence of gentamicin resistant organisms and the potential problems of aminoglycoside ototoxicity, nephrotoxicity, and poor penetration into cerebrospinal fluid (CSF) has led to third generation cephalosporin monotherapy being advocated for routine first line treatment. 2 We describe our experience of third generation cephalosporins in a unit that has continued to use ampicillin and gentamicin as first line treatment. We suggest that the routine use of third generation cephalosporins as first line treatment for suspected infection in neonatal intensive care units may be inappropriate.
Background
The regional neonatal intensive care unit, Liverpool Maternity Hospital, admits between 450 and 500 babies each year. Roughly 30% weigh less than 1500 g at birth and about 30% are outborn.
Handwashing with a chlorhexidine solution followed by application of an alcohol rub is carried out before every infant contact. Gloves are worn during nursing procedures and napkin changes. Routine infection surveillance includes culture and sensitivity testing on daily specimens of tracheal aspirate from intubated babies and weekly rectal and superficial swabs from all babies. A full infection screen, consisting of superficial swabbing and urine, CSF, and blood cultures, is carried out on all outborn babies on admission. 
part to the increasing presence of gentamicin resistant organisms4 5 but also to the potential hazards of ototoxicity and nephrotoxicity in an already vulnerable population; in addition, the aminoglycosides penetrate into CSF poorly. Because of these reservations the use of the third generation cephalosporins, which are relatively non-toxic and penetrate well into CSF, has been advocated as suitable first line monotherapy in neonatal intensive care units.2
The third generation cephalosporins are betalactam antibiotics that have an expanded range of antibiotic activity. Unfortunately, since their introduction several clinical problems have emerged. These include the development of resistance by the infecting organism during treatment and the concurrent development of cross resistance to most other beta-lactam antibiotics.6 7 A substantial proportion of strains of E. cloacae are resistant to the second generation cephalosporin cefuroxime and the increased use of this antibiotic for Staph. epidermidis infections was undoubtedly responsible for the selection of such resistant strains, with a consequent increase in numbers of infants colonised with E. cloacae. This enlarging reservoir of E. cloacae thus consisted of organisms resistant to cefuroxime but sensitive to the third generation cephalosporins cefotaxime and ceftazidime. Concurrent with the increasing number of infants colonised with E. cloacae, however, strains resistant to cefotaxime and ceftazidime occurred.
The possibility of introduction of strains of E. cloacae resistant to the third generation cephalosporins from outside the unit was unlikely as all outborn babies underwent a full infection screen on admission. Furthermore, the biotypes of the isolates were identical.
Production of beta-lactamase activity may be either plasmid or chromosomally mediated; the oxime cephalosporins, cefotaxime and ceftazidime, show a high degree of stability to plasmid encoded beta-lactamase activities and are also relatively resistant to the normal amounts of chromosomally mediated cephalosporinase activities found in most wild type Enterobacteriacae.8 If these amounts are increased, however, either by exposure of the wild type to a beta-lactamase inducer (reversible derepression) or mutation to the stably derepressed state, most third generation cephalosporins may be inactivated.9 1( Both second and third generation cephalosporins are inducers of cephalosporinase activities in the genera Pseudomonas, Serratia, and Enterobacter, which possess chromosomally mediated inducible beta-lactamase activities (type Ii).7
Both mechanisms of increased production of beta-lactamase activity may have played a part in the outbreak of infection described. E. cloacae resistant to the third generation cephalosporins were isolated from seven babies on routine screening swabs. At the time of isolation none had been on treatment with a cephalosporin. This observation suggests nosocomial transmission, although this cannot be proved as no information regarding serotypes was available. The biotypes of the isolates were, however, identical. As induction requires the continuing presence of the inducer, with induction ceasing when the inducer is removed, induction of beta-lactamase activity was probably not involved here; the passage of a derepressed mutant is a possibility.
In four of the five infants with systemic infection treated with cefotaxime E. cloacae resistant to cefotaxime and cefotazidime were first isolated after the start of treatment (Table) . Once again, though the possibility of multiple strains exists, reversible induction of production of beta-lactamase activity was probably responsible for the occurrence of resistance here. This is supported by the observation that in the three infants who survived E. cloacae isolated after exposure to cefotaxime had ceased was again sensitive to the third generation cephalosporins.
The emergence of cefotaxime resistance during treatment with this antibiotic is recognised5 7 Our observations once again illustrate the importance of routine bacteriological surveillance in a neonatal intensive care unit.14 Routine surveillance also permits the introduction of alternative first line treatment regimens on a rotational basis.
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